🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Prof Stephen Freedland, MD discusses his latest publications in European Urology👇 Cancer at Cedars-Sinai Cedars-Sinai Academic Medicine

👏Delighted to host Christopher Wallis (he/him/his) this morning for our departmental Grand Rounds! Univ of Toronto Urology Mount Sinai Department of Urology

Prof Karyn Eilber was interviewed in Urology Times !

Such a pleasure to speak to such an esteemed department! Thank you for having me.

🚨Exercise after #cancer diagnosis🚨 🏋️‍♀️🏋️‍♂️Ask any of my patients with cancer & you'll hear I always encourage fitness ✍️This new work in JNCI shows exercise after a new cancer diagnosis is associated with longer survival 👉This was true for patients with many GU cancers

Prof Stephen Freedland, MD chats with UroToday.com about recent data from the EMBARK trial 👇 Cancer at Cedars-Sinai

Tom Powles #ctDNA of periop durva + NAC in #MIBC (Ph III NIAGARA) ➡️ Natera ctDNA baseline and clearance prognostic of EFS (improved in durva arm), post-RC ctDNA prognostic of DFS, pre-RC ctDNA- NOT predictive of pCR #ASCO25 OncoAlert

ANZUP rand PhIII ANZUP 1301 of intravesical MMC + BCG vs BCG in tx-naive #HR-NMIBC ➡️ no sig diff in DFS, time to recurrence or progression, or OS between arms. Post-hoc suggests MMC addition may benefit in higher-risk (all T1, CIS) subgroup #ASCO25 OncoAlert

Dr. Dhanawat rand PhIII non-inferiority trial of adj platinum/5-FU vs platinum/paclitaxel after resected #penilecancer ➡️ due to slow accrual, study closed. Numerical improvements in PFS, OS in favor of paclitaxel arm. Applause for this trial in rare tumor #ASCO25 OncoAlert

Praful Ravi #ICECAP meta-analysis shows addition of docetaxel to RT + long-term ADT in high-risk localized #prostatecancer does not significantly improve OS and MFS, modest benefits in EFS/PCSM #ASCO25 OncoAlert

PhII rand Metacure trial of oligo #mCSPC SBRT to all mets + ADT + apa +/- abi ➡️ PSA0 w/T recovery (primary endpt) met with 42% with short ADT + apa and 50% w/short course ADT + apa and combined group with abi #ASCO25 OncoAlert

No clear benefit to adding docetaxel to long term ADT for high-risk or very high-risk #prostatecancer patients getting #radiation. Can use #abiraterone for the highest risk groups, but still an unmet need of how to improve outcomes for these patients. #ASCO2025

Excited to present new data from #EMBARK showing that in high risk BCR #prostatecancer patients that #enzalutamide alone has clinical benefits regardless of how you got to high risk BCR. #ASCO25

Important real world data that even if PSA drops 90% in mHSPC - that is not good enough unless PSA is <0.2. Let’s set the bar correctly! <0.2 is the goal - anything less is not good enough. ADT + ARPI much more likely to get PSA <0.2. #ASCO25

Phase 3 of novel viral vector in #prostatecancer pts getting XRT. Intermediate to high-risk. Despite slide title - only helps w/o ADT but not w/ADT. Curves separate at 24 mos when biopsies done. Unlikely to help high risk w/ADT but may replace ADT for intermediate risk? #ASCO25

Nice analysis from IRONMAN matching our VA results presented yesterday: in mHSPC - if the PSA is not <0.2 that is bad. Let’s set the bar correctly- the goal is PSA <0.2. PSA <0.1 does even better! #ASCO25

Updated results from #ARCHES in mHSPC showing sustained benefits of #enzalutamide with minimum 5 year followup. 3 year survival benefit in high volume disease! Amazing results! Andrew Armstrong Arun Azad #ASCO25

Associate prof Timothy Daskivich discussed his recent publication in JAMA Internal Medicine w/ UroToday.com 👇 Cancer at Cedars-Sinai Cedars-Sinai Academic Medicine Cedars-Sinai

👏Congratulations Prof Dolores Di Vizio on your publication in Cell Reports Medicine on large oncosomes in multiple cancers with a deep dive in #prostatecancer 🔗shorturl.at/cSWxZ Boutroslab Edwin Posadas, MD Cancer at Cedars-Sinai Prostate Cancer Foundation

🚨Shared-decision making (SDM) for #prostatecancer🚨 ☝️Guidelines support SDM when it comes to choosing treatment 💡Associate prof Timothy Daskivich analyzed 50 convos between MDs & patients to standardize SDM Urology Gold Journal 🔗 shorturl.at/XAqqv